MedTrace Logo

Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma

NCT00257465 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2015-12-03

No results posted yet for this study

Summary

The purpose of this study is to determine whether a vaccine composed of patients' own melanoma cells treated with the chemical, dinitrophenyl (DNP)(called a hapten), is safe and stimulates an immune response to patients' own cancer cells.

Conditions

Interventions

BIOLOGICAL

Autologous, DNP-modified vaccine (M-Vax)

5.0, 2.5, 0.5, or 0 cells

BIOLOGICAL

Autologous, DNP-Modified Melanoma Vaccine

5 million cells

BIOLOGICAL

Autologous, DNP-Modified Vaccine

2.5 million cells

BIOLOGICAL

Autologous, DNP-Modified Vaccine

0.5 million cells

BIOLOGICAL

Autologous, DNP-Modified Vaccine

0 cells

Sponsors & Collaborators

  • AVAX Technologies

    lead INDUSTRY

Principal Investigators

  • David Berd, MD · AVAX Technologies

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00257465 on ClinicalTrials.gov